Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marine Gilabert

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Oncotarget|March 24, 2015
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinomaMaria Inés Molejon, Juan Ignacio Tellechea, Celine Loncle, et al.
BMC Cancer|January 7, 2022
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patientsSébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, et al.
Clinical Colorectal Cancer|May 3, 2017
Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative StudyYoung Soo Rho, Marine Gilabert, Karol Polom, et al.
The Journal of Surgical Research|December 5, 2020
Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a StudiesSalvatore Paiella, Luca Casetti, Jacques Ewald, et al.
The American Journal of Pathology|March 14, 2015
Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinomaPauline Duconseil, Marine Gilabert, Odile Gayet, et al.
The Oncologist|June 2, 2019
Characteristics of <i>BRAF</i><sup></sup> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2018
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)Cindy Neuzillet, Sébastien Gaujoux, Nicolas Williet, et al.
Oncotarget|December 8, 2014
A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitorOdile Gayet, Celine Loncle, Pauline Duconseil, et al.
Revue Medicale Suisse|February 2, 2022
[2021 Oncology update]May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Oncotarget|July 28, 2016
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPTMarine Barraud, Jonathan Garnier, Celine Loncle, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Oncotarget|March 24, 2015
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinomaMaria Inés Molejon, Juan Ignacio Tellechea, Celine Loncle, et al.
BMC Cancer|January 7, 2022
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patientsSébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, et al.
Clinical Colorectal Cancer|May 3, 2017
Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative StudyYoung Soo Rho, Marine Gilabert, Karol Polom, et al.
The Journal of Surgical Research|December 5, 2020
Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a StudiesSalvatore Paiella, Luca Casetti, Jacques Ewald, et al.
The American Journal of Pathology|March 14, 2015
Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinomaPauline Duconseil, Marine Gilabert, Odile Gayet, et al.
The Oncologist|June 2, 2019
Characteristics of <i>BRAF</i><sup></sup> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2018
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)Cindy Neuzillet, Sébastien Gaujoux, Nicolas Williet, et al.
Oncotarget|December 8, 2014
A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitorOdile Gayet, Celine Loncle, Pauline Duconseil, et al.
Revue Medicale Suisse|February 2, 2022
[2021 Oncology update]May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Oncotarget|July 28, 2016
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPTMarine Barraud, Jonathan Garnier, Celine Loncle, et al.
Pageof 7